---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122475"
form_type: "8-K"
ticker: "ASH"
cik: "0001674862"
company_name: "ASHLAND INC."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:38:31.785058+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Ashland Q4 sales $522M (+1% YoY), adj. EBITDA $124M (+68%), issues FY2025 outlook

## Summary
- Sales $522M, up 1% YoY; nutraceuticals divestiture and CMC/MC curtailments reduced sales ~$24M (5%).
- Adjusted EBITDA $124M (+68% YoY); below expectations due to HEC startup issues (~$5M) and weak China coatings demand.
- Net income $16M vs $(4)M; adjusted EPS ex-intangibles $1.26, up from $0.41 YoY.
- Bought back 1.7M shares in Q4; $620M remains under evergreen authorization. Cash from ops $80M; ongoing FCF $88M.
- Sold nutraceuticals to Turnspire Capital; production at U.S. cellulosic site normalized early October.

## SEC filing metadata
- accession: 0000950170-24-122475
- form_type: 8-K
- ticker: ASH
- cik: 0001674862
- company_name: ASHLAND INC.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674862/000095017024122475/0000950170-24-122475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674862/000095017024122475/ash-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122475
- JSON: https://secwatch.observer/filing/0000950170-24-122475.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122475.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.